| Clinical overview of MDM2/X-targeted therapies A Burgess, KM Chia, S Haupt, D Thomas, Y Haupt, E Lim Frontiers in oncology 6, 7, 2016 | 399 | 2016 |
| Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis S Masaldan, SAS Clatworthy, C Gamell, PM Meggyesy, AT Rigopoulos, ... Redox biology 14, 100-115, 2018 | 379 | 2018 |
| MDM4 is a key therapeutic target in cutaneous melanoma A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ... Nature medicine 18 (8), 1239-1247, 2012 | 379 | 2012 |
| Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation DS Liu, CP Duong, S Haupt, KG Montgomery, CM House, WJ Azar, ... Nature communications 8 (1), 14844, 2017 | 327 | 2017 |
| Tumour suppression by p53: the importance of apoptosis and cellular senescence V Zuckerman, K Wolyniec, RV Sionov, S Haupt, Y Haupt The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 298 | 2009 |
| Sex disparities matter in cancer development and therapy S Haupt, F Caramia, SL Klein, JB Rubin, Y Haupt Nature Reviews Cancer 21 (6), 393-407, 2021 | 228 | 2021 |
| Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities M Kollareddy, E Dimitrova, KC Vallabhaneni, A Chan, T Le, KM Chauhan, ... Nature communications 6 (1), 7389, 2015 | 143 | 2015 |
| The major surface antigens of Entamoeba histolytica trophozoites are GPI-anchored proteophosphoglycans S Moody-Haupt, JH Patterson, D Mirelman, MJ McConville Journal of molecular biology 297 (2), 409-420, 2000 | 136 | 2000 |
| E6AP promotes the degradation of the PML tumor suppressor I Louria-Hayon, O Alsheich-Bartok, Y Levav-Cohen, I Silberman, M Berger, ... Cell Death & Differentiation 16 (8), 1156-1166, 2009 | 115 | 2009 |
| Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ... Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019 | 109 | 2019 |
| APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma DSH Liu, M Read, C Cullinane, WJ Azar, CM Fennell, KG Montgomery, ... Gut 64 (10), 1506-1516, 2015 | 109 | 2015 |
| Regulation of mutant p53 protein expression R Vijayakumaran, KH Tan, PJ Miranda, S Haupt, Y Haupt Frontiers in oncology 5, 284, 2015 | 106 | 2015 |
| Role of p53 in the progression of gastric cancer RA Busuttil, GV Zapparoli, S Haupt, C Fennell, SQ Wong, JMB Pang, ... Oncotarget 5 (23), 12016, 2014 | 104 | 2014 |
| C-Abl as a modulator of p53 Y Levav-Cohen, Z Goldberg, V Zuckerman, T Grossman, S Haupt, ... Biochemical and Biophysical Research Communications 331 (3), 737-749, 2005 | 98 | 2005 |
| PML enhances the regulation of p53 by CK1 in response to DNA damage O Alsheich-Bartok, S Haupt, I Alkalay-Snir, S Saito, E Appella, Y Haupt Oncogene 27 (26), 3653-3661, 2008 | 93 | 2008 |
| P53: a guardian of immunity becomes its saboteur through mutation AD Agupitan, P Neeson, S Williams, J Howitt, S Haupt, Y Haupt International journal of molecular sciences 21 (10), 3452, 2020 | 86 | 2020 |
| Mdm2 in growth signaling and cancer: mini review Y Levav-Cohen, S Haupt, Y Haupt Growth Factors 23 (3), 183-192, 2005 | 83 | 2005 |
| Promyelocytic leukemia protein is required for gain of function by mutant p53 S Haupt, S di Agostino, I Mizrahi, O Alsheich-Bartok, M Voorhoeve, ... Cancer research 69 (11), 4818-4826, 2009 | 81 | 2009 |
| The role of MDM2 and MDM4 in breast cancer development and prevention S Haupt, R Vijayakumaran, PJ Miranda, A Burgess, E Lim, Y Haupt Journal of molecular cell biology 9 (1), 53-61, 2017 | 79 | 2017 |
| Mutant p53 drives cancer by subverting multiple tumor suppression pathways S Haupt, D Raghu, Y Haupt Frontiers in oncology 6, 12, 2016 | 79 | 2016 |
